U.S. Office — Brooklyn, NY · Mon–Fri 9:00–18:00 ET
Direct: +1 (347) 567-0781 · Email: info@sucotondusa.com
ProductsAboutCertificationsVerify FactoryBlogContact
About Sucotond USA

A U.S. project office connected directly to the production team.

Sucotond USA is the Brooklyn sales and project-coordination office for private label functional gummy programs manufactured at Sucotond (Guangzhou) Health Biotechnology Co., Ltd. The office and production facility have different responsibilities, and buyers should be able to verify both.

Gummy production and packaging area at the overseas production facilityTwo Roles, One Project
U.S. officeBrooklyn, New York
Production facilityGuangzhou, China
U.S. responsibilityBuyer and project coordination
Factory responsibilityDevelopment, production and batch control
Responsibility Map

Know who owns each step

Clear ownership reduces delays and prevents a sales conversation from being mistaken for product-specific approval.

Brooklyn project office

Coordinates initial requirements, commercial communication, quotation, document requests, project status and delivery planning during Eastern Time business hours.

Overseas production facility

Handles formulation development, production feasibility, manufacturing, in-process controls, batch records and the agreed finished-product testing workflow.

Project Path

From non-confidential brief to commercial batch

1. Define the target

Share the active, serving, gummy base, package, quantity, market and timing.

2. Review feasibility

Identify the open formulation, process, testing and commercial questions.

3. Approve the sample

Translate the reviewed sample into a written commercial specification.

4. Confirm documents

Agree the release test panel, packaging records and project-specific document package.

5. Produce and release

Execute the commercial batch against the approved requirements and agreed controls.

6. Coordinate delivery

Track the handoff, freight assumptions and delivery communication through the U.S. office.

Evidence Before Claims

What buyers can verify independently

Factory identity

Match the legal production-facility name and address to the public NSF listing.

Certification scope

Check the issuing body, facility holder, category scope and current document before relying on a badge.

Project evidence

Request the formula-specific specification, sample identity, test plan and applicable batch records.

Who · How · Why

How Sucotond USA prepares buyer-facing content

These pages are commercial project-coordination materials from a seller, not independent regulator, laboratory, legal adviser or medical publisher. The method below makes that perspective and its evidence limits visible.

Who publishes it

Sucotond USA's Brooklyn project-coordination office publishes the U.S. buyer guides. The Guangzhou facility is responsible for manufacturing work and project-specific technical records. A named personal reviewer is shown only when that person and review actually exist.

How evidence is handled

Use the closest primary source available: FDA or eCFR requirements, NIH datasets, issuer-controlled certification records, public identity records and formula- or batch-specific documents. Page-specific sources support only the statement they address; they do not create product approval or a universal manufacturing result.

Why the page exists

Each page must help a supplement brand complete a procurement, specification, testing, packaging or evidence decision. A page is not justified merely by a keyword variation, competitor URL or desired word count.

Automation and QA

Automation may assist drafting, data processing, code and deterministic QA. Publication gates check canonical URLs, structured data, links, source boundaries, cross-domain overlap and measurable handoffs. Those gates are not human medical, legal, regulatory or laboratory review.

Updates and corrections

The visible date and dateModified value should change only after a substantive page update—not to manufacture freshness. If a source, calculation or responsibility statement needs correction, email info@sucotondusa.com with the page URL and the exact issue.

Commercial perspective: Sucotond USA coordinates projects for its related Guangzhou production facility. Buyers should independently verify identity, scope, issuer status and the exact project evidence before making a supplier or product decision.

Official Web Roles

Use the right Sucotond site for the right team.

Separate web roles help buyers and search engines distinguish the Brooklyn project office from the Guangzhou manufacturing company. A statement on either site is not a substitute for current, project-specific evidence.

sucotondusa.com

This is the U.S. office website for American buyer inquiries, preliminary project scoping, quotation coordination and document requests.

Contact the Brooklyn project office →

sucotond.com

This is the Guangzhou company's website. Manufacturing identity, facility qualification and project evidence should still be checked against the issuing source and the applicable commercial specification.

Visit the Guangzhou company website →

Independent Identity References

Verify the office and factory as separate entities.

These public profiles help buyers distinguish the Brooklyn project office from the Guangzhou manufacturing entity. They do not replace project-specific qualification or batch evidence.

Sucotond USA company profile

The independent BevNET/Nombase directory profile identifies Sucotond USA and links back to this website.

Open the Sucotond USA directory profile →

Manufacturing-company identity

The LinkedIn company page identifies Sucotond (Guangzhou) Health Biotechnology Co., Ltd. and its manufacturing role.

Open the factory company profile →

The official USPTO TSDR record for SUCOTOND NUTRITION separately identifies the same Guangzhou legal entity as the current owner and shows U.S. registration number 7786820.

Open the official USPTO trademark record →

This is trademark-owner identity evidence—not product approval, facility certification or project-performance evidence.

Start With the U.S. Office

Bring us a product question, not a finished answer.

A short brief with target dose, package, volume and timing is enough for a preliminary non-confidential review.

Start the Conversation